Events

SANT mission to Poland: medicine security and the future of European manufacturing in focus

2 April 2026

On 31 March 2026, a delegation of Members of the European Parliament on a mission of the European Parliament’s Committee on Public Health (SANT) visited Adamed’s Manufacturing and Logistics Centre in Pabianice. The visit provided an opportunity to discuss how Europe can rebuild its medicine security by supporting European pharmaceutical manufacturers. This is essential to ensure stable access to treatment for patients across Europe. 

The delegation included Adam Jarubas, Vytenis Povilas Andriukaitis, Justyna Szczepańska, Marek Kołodziejski, Witold Naturski and Alina Ionascu. The delegation was also accompanied by MP Jolanta Zięba-Gzik and Aleksandra Jarmakowska-Jasiczek, Deputy Mayor of Pabianice. 

MEPs visit Adamed’s manufacturing facility 

The visit to Pabianice took place on the second day of the SANT mission to Poland. The European Parliament delegation toured the production area, quality control facilities, the inhaled medicines laboratory, the packaging area and the microbiology laboratory. 

Committee Chair Adam Jarubas emphasised that visits to production facilities help MEPs better understand the industries for which they create legislation: “Our presence here today shows that Adamed is an example of investment development, corporate social responsibility and good relations with the local community. We want to listen to the industry as often as possible and obtain specific information, reliable assessments and a realistic evaluation of the situation. The European Union sometimes balances between over-regulation and failure to see the full picture. We also know that the countries of the so-called old Union have an established position in this market, which makes it even more important for us to advocate consistently and effectively for the interests of Central and Eastern Europe, including in the context of medicine security.” 

Challenges facing the European pharmaceutical sector 

The delegation took part in a discussion on the challenges facing the European pharmaceutical sector. The main issues identified included Europe’s growing dependence on Asia for generic active pharmaceutical ingredients, inconsistent legislation, the gold-plating of EU rules in national systems, the absence of medicine-security coordinators and insufficient incentives to support the competitiveness of medicines made in the EU. 

Another challenge is the mismatch between EU programmes such as STEP and FENG and the specific characteristics of the pharmaceutical sector. 

“We need support for the development of the pharmaceutical industry, not only in research and development but also in manufacturing. If Europe wants to compete effectively on the global market, it needs stable and predictable financing mechanisms. Today these are missing, even though they would support the restoration of Europe’s pharmaceutical independence,” said Katarzyna Dubno, External Relations, ESG and Health Economics Director at Adamed Pharma. 

“Above all, we need consistent regulations. Without them, the European pharmaceutical sector will not be competitive. Meanwhile, some EU regulations, including the Urban Wastewater Treatment Directive, introduce additional and often very costly burdens for manufacturers,” said Magdalena Krakowiak, International External Relations Manager at Adamed Pharma. 

Vytenis Povilas Andriukaitis added: “Innovative solutions are also developed in the field of generic medicines. We must build a system in which research, investment and innovation cover all types of activity. Global competition is very strong, which is why we need regulations that ensure a level playing field and support innovation at every stage of development.” 

Adamed: a Polish manufacturer with an international reach 

Adamed is one of Poland’s largest pharmaceutical manufacturers and produces 3.6 billion tablets annually. The company has eight representative offices worldwide and a factory in Vietnam. In the second half of the year, the Riells plant in Spain, which Adamed is acquiring from Sanofi, will join the Group. 

During the SANT mission, MEPs meet representatives of the healthcare sector and visit sites connected with pharmaceutical manufacturing and healthcare systems. The objective is to improve access to medicines and build more resilient healthcare systems in the EU.